Therapy of chronic hepatitis B;Le point sur le traitement antiviral de l'hépatite B chronique

Revue Medicale Suisse

Volumn 2, Issue 77, 2006, Pages 1981-1985

  Negro, Francesco ^a   Hadengue, Antoine ^a  

^a HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; LAMIVUDINE; PEGINTERFERON; RNA DIRECTED DNA POLYMERASE; TENOFOVIR;

DISEASE ACTIVITY; DISEASE COURSE; HEPATITIS B; HUMAN; INFECTION RISK; REVIEW; SWITZERLAND; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS;

EID: 33748950629     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement J Hepatol 2003;39 (Suppl. 1):S3-25.
2. Perrillo RP. Therapy of hepatitis B - viral suppression or eradication? Hepatology 2006;43(2 Suppl. 1):S182-93.
3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
5. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:A randomised trial. Lancet 2005;365:123-9.
6. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, Lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis. N Engl J Med 2004;351:1206-17.
7. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5.
8. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36.
9. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
10. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
11. Wang C, Corey L, Leung N, et al. Antiviral activity of 48 weeks of emtricitabine treatment in patients with HBeAg negative/HBV DNA positive chronic Hepatitis B. Hepatology 2001;34:323A.
12. Lim SG, Ng TM, Kung N, et al. Emtricitabine FTCB-301 Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166:49-56.